#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-9	Capturing	_
1-2	10-21	spontaneous	_
1-3	22-30	activity	_
1-4	31-33	in	_
1-5	34-37	the	_
1-6	38-44	medial	_
1-7	45-55	prefrontal	_
1-8	56-62	cortex	_
1-9	63-68	using	_
1-10	69-82	near-infrared	_
1-11	83-95	spectroscopy	_
1-12	96-99	and	_
1-13	100-103	its	_
1-14	104-115	application	_
1-15	116-118	to	_
1-16	119-132	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-17	133-146	Near-infrared	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy
1-18	147-159	spectroscopy	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy
1-19	160-161	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy
1-20	162-166	NIRS	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy
1-21	167-168	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy
1-22	169-171	is	_
1-23	172-174	an	_
1-24	175-182	optimal	_
1-25	183-190	imaging	_
1-26	191-199	modality	_
1-27	200-204	used	_
1-28	205-207	to	_
1-29	208-215	examine	_
1-30	216-227	spontaneous	_
1-31	228-233	brain	_
1-32	234-242	activity	_
1-33	243-250	because	_
1-34	251-253	it	_
1-35	254-257	can	_
1-36	258-265	quietly	_
1-37	266-273	measure	_
1-38	274-279	blood	_
1-39	280-284	flow	_
1-40	285-292	changes	_
1-41	293-297	with	_
1-42	298-302	less	_
1-43	303-311	physical	_
1-44	312-323	restriction	_
1-45	324-330	during	_
1-46	331-334	the	_
1-47	335-342	resting	_
1-48	343-348	state	_
1-49	349-350	.	_

2-1	351-355	Here	_
2-2	356-357	,	_
2-3	358-362	NIRS	_
2-4	363-366	was	_
2-5	367-371	used	_
2-6	372-374	at	_
2-7	375-379	rest	_
2-8	380-382	to	_
2-9	383-390	measure	_
2-10	391-402	spontaneous	_
2-11	403-411	activity	_
2-12	412-414	in	_
2-13	415-418	the	_
2-14	419-425	medial	_
2-15	426-436	prefrontal	_
2-16	437-443	cortex	_
2-17	444-445	(	_
2-18	446-450	mPFC	_
2-19	451-452	)	_
2-20	453-454	,	_
2-21	455-456	a	_
2-22	457-461	main	_
2-23	462-467	locus	_
2-24	468-470	of	_
2-25	471-478	default	_
2-26	479-483	mode	_
2-27	484-491	network	_
2-28	492-493	.	_

3-1	494-504	Consistent	_
3-2	505-509	with	_
3-3	510-518	previous	_
3-4	519-523	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-5	524-531	studies	_
3-6	532-533	,	_
3-7	534-543	magnitude	_
3-8	544-546	of	_
3-9	547-550	the	_
3-10	551-562	spontaneous	_
3-11	563-571	activity	_
3-12	572-574	in	_
3-13	575-579	this	_
3-14	580-586	region	_
3-15	587-595	declined	_
3-16	596-600	with	_
3-17	601-611	increasing	_
3-18	612-615	age	_
3-19	616-618	in	_
3-20	619-626	healthy	_
3-21	627-635	subjects	_
3-22	636-637	.	_

4-1	638-641	The	_
4-2	642-651	magnitude	_
4-3	652-659	reduced	_
4-4	660-662	in	_
4-5	663-666	the	_
4-6	667-671	mPFC	_
4-7	672-674	of	_
4-8	675-683	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-9	684-688	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-10	689-702	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-11	703-704	.	_

5-1	705-717	Additionally	_
5-2	718-719	,	_
5-3	720-722	in	_
5-4	723-726	the	_
5-5	727-731	mPFC	_
5-6	732-734	of	_
5-7	735-743	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-8	744-748	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-9	749-762	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-10	763-764	,	_
5-11	765-768	the	_
5-12	769-780	spontaneous	_
5-13	781-789	activity	_
5-14	790-793	did	_
5-15	794-797	not	_
5-16	798-802	show	_
5-17	803-806	any	_
5-18	807-818	age-related	_
5-19	819-826	decline	_
5-20	827-828	;	_
5-21	829-832	the	_
5-22	833-841	activity	_
5-23	842-845	was	_
5-24	846-853	already	_
5-25	854-857	low	_
5-26	858-860	in	_
5-27	861-868	younger	_
5-28	869-877	patients	_
5-29	878-879	.	_

6-1	880-887	Further	_
6-2	888-896	analysis	_
6-3	897-902	using	_
6-4	903-913	fractional	_
6-5	914-923	amplitude	_
6-6	924-926	of	_
6-7	927-940	low-frequency	_
6-8	941-953	fluctuations	_
6-9	954-963	confirmed	_
6-10	964-967	the	_
6-11	968-977	reduction	_
6-12	978-980	of	_
6-13	981-992	spontaneous	_
6-14	993-1001	activity	_
6-15	1002-1004	in	_
6-16	1005-1008	the	_
6-17	1009-1013	mPFC	_
6-18	1014-1016	of	_
6-19	1017-1025	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-20	1026-1030	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-21	1031-1044	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-22	1045-1046	,	_
6-23	1047-1057	consistent	_
6-24	1058-1062	with	_
6-25	1063-1066	the	_
6-26	1067-1075	findings	_
6-27	1076-1078	of	_
6-28	1079-1083	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-29	1084-1091	studies	_
6-30	1092-1093	.	_

7-1	1094-1097	Our	_
7-2	1098-1106	findings	_
7-3	1107-1118	demonstrate	_
7-4	1119-1122	the	_
7-5	1123-1130	ability	_
7-6	1131-1133	of	_
7-7	1134-1138	NIRS	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
7-8	1139-1141	to	_
7-9	1142-1150	evaluate	_
7-10	1151-1154	the	_
7-11	1155-1166	spontaneous	_
7-12	1167-1175	activity	_
7-13	1176-1178	in	_
7-14	1179-1182	the	_
7-15	1183-1187	mPFC	_
7-16	1188-1190	of	_
7-17	1191-1199	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
7-18	1200-1204	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
7-19	1205-1218	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
7-20	1219-1220	,	_
7-21	1221-1233	particularly	_
7-22	1234-1241	younger	_
7-23	1242-1250	patients	_
7-24	1251-1252	.	_

8-1	1253-1264	Considering	_
8-2	1265-1268	the	_
8-3	1269-1275	safety	_
8-4	1276-1279	and	_
8-5	1280-1284	ease	_
8-6	1285-1287	of	_
8-7	1288-1291	the	_
8-8	1292-1296	NIRS	_
8-9	1297-1309	measurements	_
8-10	1310-1311	,	_
8-11	1312-1315	the	_
8-12	1316-1323	current	_
8-13	1324-1328	NIRS	_
8-14	1329-1334	study	_
8-15	1335-1337	of	_
8-16	1338-1341	the	_
8-17	1342-1355	resting-state	_
8-18	1356-1364	activity	_
8-19	1365-1374	indicates	_
8-20	1375-1378	its	_
8-21	1379-1386	utility	_
8-22	1387-1390	for	_
8-23	1391-1399	clinical	_
8-24	1400-1412	applications	_
8-25	1413-1415	to	_
8-26	1416-1429	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-27	1430-1431	,	_
8-28	1432-1437	which	_
8-29	1438-1441	may	_
8-30	1442-1452	facilitate	_
8-31	1453-1466	chronological	_
8-32	1467-1477	assessment	_
8-33	1478-1480	of	_
8-34	1481-1487	larger	_
8-35	1488-1495	cohorts	_
8-36	1496-1498	of	_
8-37	1499-1507	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-38	1508-1512	with	_
8-39	1513-1526	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-40	1527-1529	in	_
8-41	1530-1537	further	_
8-42	1538-1545	studies	_
8-43	1546-1547	.	_

9-1	1548-1555	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
9-2	1556-1564	Subjects	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
9-3	1565-1576	Fifty-three	_
9-4	1577-1584	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
9-5	1585-1586	,	_
9-6	1587-1599	right-handed	_
9-7	1600-1605	males	_
9-8	1606-1610	aged	_
9-9	1611-1618	between	_
9-10	1619-1621	23	_
9-11	1622-1625	and	_
9-12	1626-1628	66	_
9-13	1629-1634	years	_
9-14	1635-1636	(	_
9-15	1637-1641	mean	_
9-16	1642-1643	±	_
9-17	1644-1649	s.e.m	_
9-18	1650-1651	.	_

10-1	1652-1653	=	_
10-2	1654-1658	41.1	_
10-3	1659-1660	±	_
10-4	1661-1664	1.5	_
10-5	1665-1666	)	_
10-6	1667-1671	with	_
10-7	1672-1674	no	_
10-8	1675-1682	history	_
10-9	1683-1685	of	_
10-10	1686-1698	neurological	_
10-11	1699-1701	or	_
10-12	1702-1713	psychiatric	_
10-13	1714-1723	disorders	_
10-14	1724-1736	participated	_
10-15	1737-1739	in	_
10-16	1740-1744	this	_
10-17	1745-1750	study	_
10-18	1751-1752	.	_

11-1	1753-1759	Twenty	_
11-2	1760-1772	right-handed	_
11-3	1773-1777	male	_
11-4	1778-1786	patients	_
11-5	1787-1788	(	_
11-6	1789-1794	25–68	_
11-7	1795-1800	years	_
11-8	1801-1802	,	_
11-9	1803-1807	50.6	_
11-10	1808-1809	±	_
11-11	1810-1813	3.0	_
11-12	1814-1815	)	_
11-13	1816-1828	hospitalised	_
11-14	1829-1833	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-15	1834-1847	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-16	1848-1851	and	_
11-17	1852-1858	having	_
11-18	1859-1867	apparent	_
11-19	1868-1876	deficits	_
11-20	1877-1879	in	_
11-21	1880-1886	social	_
11-22	1887-1898	functioning	_
11-23	1899-1904	based	_
11-24	1905-1907	on	_
11-25	1908-1909	a	_
11-26	1910-1913	GAF	_
11-27	1914-1919	score	_
11-28	1920-1922	of	_
11-29	1923-1926	≤35	_
11-30	1927-1931	were	_
11-31	1932-1936	also	_
11-32	1937-1945	included	_
11-33	1946-1947	.	_

12-1	1948-1951	Two	_
12-2	1952-1954	or	_
12-3	1955-1959	more	_
12-4	1960-1973	psychiatrists	_
12-5	1974-1983	diagnosed	_
12-6	1984-1988	each	_
12-7	1989-1996	patient	_
12-8	1997-1999	on	_
12-9	2000-2003	the	_
12-10	2004-2009	basis	_
12-11	2010-2012	of	_
12-12	2013-2016	the	_
12-13	2017-2022	DSM-5	_
12-14	2023-2031	criteria	_
12-15	2032-2035	for	_
12-16	2036-2049	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-17	2050-2051	.	_

13-1	2052-2055	The	_
13-2	2056-2065	diagnosis	_
13-3	2066-2069	was	_
13-4	2070-2078	verified	_
13-5	2079-2084	based	_
13-6	2085-2087	on	_
13-7	2088-2096	detailed	_
13-8	2097-2105	clinical	_
13-9	2106-2118	observations	_
13-10	2119-2125	during	_
13-11	2126-2141	hospitalisation	_
13-12	2142-2143	.	_

14-1	2144-2147	All	_
14-2	2148-2156	patients	_
14-3	2157-2161	were	_
14-4	2162-2174	administered	_
14-5	2175-2189	antipsychotics	_
14-6	2190-2191	,	_
14-7	2192-2195	and	_
14-8	2196-2200	none	_
14-9	2201-2204	had	_
14-10	2205-2206	a	_
14-11	2207-2214	history	_
14-12	2215-2217	of	_
14-13	2218-2235	substance/alcohol	_
14-14	2236-2241	abuse	_
14-15	2242-2243	.	_

15-1	2244-2252	Clinical	_
15-2	2253-2262	variables	_
15-3	2263-2265	of	_
15-4	2266-2269	the	_
15-5	2270-2278	patients	_
15-6	2279-2283	were	_
15-7	2284-2286	as	_
15-8	2287-2294	follows	_
15-9	2295-2296	:	_
15-10	2297-2300	GAF	_
15-11	2301-2306	score	_
15-12	2307-2308	,	_
15-13	2309-2313	24.2	_
15-14	2314-2315	±	_
15-15	2316-2319	1.4	_
15-16	2320-2321	;	_
15-17	2322-2329	illness	_
15-18	2330-2338	duration	_
15-19	2339-2340	,	_
15-20	2341-2345	27.9	_
15-21	2346-2347	±	_
15-22	2348-2351	3.5	_
15-23	2352-2357	years	_
15-24	2358-2359	;	_
15-25	2360-2365	onset	_
15-26	2366-2369	age	_
15-27	2370-2371	,	_
15-28	2372-2376	23.9	_
15-29	2377-2378	±	_
15-30	2379-2382	1.6	_
15-31	2383-2388	years	_
15-32	2389-2390	;	_
15-33	2391-2394	and	_
15-34	2395-2420	chlorpromazine-equivalent	_
15-35	2421-2434	antipsychotic	_
15-36	2435-2439	dose	_
15-37	2440-2441	,	_
15-38	2442-2447	804.5	_
15-39	2448-2449	±	_
15-40	2450-2455	143.7	_
15-41	2456-2462	mg/day	_
15-42	2463-2464	.	_

16-1	2465-2468	The	_
16-2	2469-2477	symptoms	_
16-3	2478-2480	of	_
16-4	2481-2484	the	_
16-5	2485-2493	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
16-6	2494-2498	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
16-7	2499-2512	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
16-8	2513-2517	were	_
16-9	2518-2526	assessed	_
16-10	2527-2532	based	_
16-11	2533-2535	on	_
16-12	2536-2551	Clinician-Rated	_
16-13	2552-2562	Dimensions	_
16-14	2563-2565	of	_
16-15	2566-2575	Psychosis	http://maven.renci.org/NeuroBridge/neurobridge#InsomniaSeverityIndex
16-16	2576-2583	Symptom	http://maven.renci.org/NeuroBridge/neurobridge#InsomniaSeverityIndex
16-17	2584-2592	Severity	http://maven.renci.org/NeuroBridge/neurobridge#InsomniaSeverityIndex
16-18	2593-2594	(	_
16-19	2595-2601	CRDPSS	_
16-20	2602-2603	)	http://maven.renci.org/NeuroBridge/neurobridge#Thing
16-21	2604-2606	by	_
16-22	2607-2610	two	_
16-23	2611-2619	research	_
16-24	2620-2633	psychiatrists	_
16-25	2634-2637	who	_
16-26	2638-2642	were	_
16-27	2643-2650	blinded	_
16-28	2651-2653	to	_
16-29	2654-2657	the	_
16-30	2658-2662	NIRS	_
16-31	2663-2667	data	_
16-32	2668-2669	,	_
16-33	2670-2675	along	_
16-34	2676-2680	with	_
16-35	2681-2684	the	_
16-36	2685-2696	information	_
16-37	2697-2705	obtained	_
16-38	2706-2710	from	_
16-39	2711-2714	the	_
16-40	2715-2723	clinical	_
16-41	2724-2736	psychiatrist	_
16-42	2737-2739	in	_
16-43	2740-2746	charge	_
16-44	2747-2750	and	_
16-45	2751-2755	ward	_
16-46	2756-2762	nurses	_
16-47	2763-2764	.	_

17-1	2765-2768	The	_
17-2	2769-2775	CRDPSS	_
17-3	2776-2782	scores	_
17-4	2783-2787	were	_
17-5	2788-2790	as	_
17-6	2791-2798	follows	_
17-7	2799-2800	;	_
17-8	2801-2815	Hallucinations	_
17-9	2816-2817	(	_
17-10	2818-2822	mean	_
17-11	2823-2824	±	_
17-12	2825-2830	s.e.m	_
17-13	2831-2832	.	_

18-1	2833-2834	=	_
18-2	2835-2838	2.5	_
18-3	2839-2840	±	_
18-4	2841-2844	0.3	_
18-5	2845-2846	,	_
18-6	2847-2856	Delusions	_
18-7	2857-2858	(	_
18-8	2859-2862	2.6	_
18-9	2863-2864	±	_
18-10	2865-2868	0.2	_
18-11	2869-2870	)	_
18-12	2871-2872	,	_
18-13	2873-2885	Disorganized	_
18-14	2886-2892	speech	_
18-15	2893-2894	(	_
18-16	2895-2898	3.0	_
18-17	2899-2900	±	_
18-18	2901-2904	0.2	_
18-19	2905-2906	)	_
18-20	2907-2908	,	_
18-21	2909-2917	Abnormal	_
18-22	2918-2929	psychomotor	_
18-23	2930-2939	behaviour	_
18-24	2940-2941	(	_
18-25	2942-2945	2.5	_
18-26	2946-2947	±	_
18-27	2948-2951	0.2	_
18-28	2952-2953	)	_
18-29	2954-2955	,	_
18-30	2956-2964	Negative	_
18-31	2965-2973	symptoms	_
18-32	2974-2975	(	_
18-33	2976-2979	3.3	_
18-34	2980-2981	±	_
18-35	2982-2985	0.2	_
18-36	2986-2987	)	_
18-37	2988-2989	,	_
18-38	2990-2998	Impaired	_
18-39	2999-3008	cognition	_
18-40	3009-3010	(	_
18-41	3011-3014	3.2	_
18-42	3015-3016	±	_
18-43	3017-3020	0.2	_
18-44	3021-3022	)	_
18-45	3023-3024	,	_
18-46	3025-3035	Depression	_
18-47	3036-3037	(	_
18-48	3038-3041	0.9	_
18-49	3042-3043	±	_
18-50	3044-3047	0.1	_
18-51	3048-3049	)	_
18-52	3050-3053	and	_
18-53	3054-3059	Mania	_
18-54	3060-3061	(	_
18-55	3062-3065	0.3	_
18-56	3066-3067	±	_
18-57	3068-3071	0.2	_
18-58	3072-3073	)	_
18-59	3074-3075	.	_

19-1	3076-3077	A	_
19-2	3078-3086	complete	_
19-3	3087-3098	description	_
19-4	3099-3101	of	_
19-5	3102-3105	the	_
19-6	3106-3111	study	_
19-7	3112-3115	was	_
19-8	3116-3124	provided	_
19-9	3125-3126	,	_
19-10	3127-3130	and	_
19-11	3131-3138	written	_
19-12	3139-3147	informed	_
19-13	3148-3155	consent	_
19-14	3156-3159	was	_
19-15	3160-3168	obtained	_
19-16	3169-3173	from	_
19-17	3174-3177	all	_
19-18	3178-3186	subjects	_
19-19	3187-3188	.	_

20-1	3189-3192	The	_
20-2	3193-3198	study	_
20-3	3199-3202	was	_
20-4	3203-3211	approved	_
20-5	3212-3214	by	_
20-6	3215-3218	the	_
20-7	3219-3225	Ethics	_
20-8	3226-3235	Committee	_
20-9	3236-3238	of	_
20-10	3239-3242	the	_
20-11	3243-3249	Kindai	_
20-12	3250-3260	University	_
20-13	3261-3268	Faculty	_
20-14	3269-3271	of	_
20-15	3272-3280	Medicine	_
20-16	3281-3284	and	_
20-17	3285-3288	was	_
20-18	3289-3298	conducted	_
20-19	3299-3301	in	_
20-20	3302-3312	accordance	_
20-21	3313-3317	with	_
20-22	3318-3321	the	_
20-23	3322-3330	relevant	_
20-24	3331-3341	guidelines	_
20-25	3342-3345	and	_
20-26	3346-3357	regulations	_
20-27	3358-3359	.	_

21-1	3360-3373	Near-infrared	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy
21-2	3374-3386	spectroscopy	_
21-3	3387-3391	NIRS	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
21-4	3392-3404	measurements	_
21-5	3405-3409	were	_
21-6	3410-3419	conducted	_
21-7	3420-3425	using	_
21-8	3426-3427	a	_
21-9	3428-3438	10-channel	_
21-10	3439-3443	NIRS	_
21-11	3444-3450	device	_
21-12	3451-3452	(	_
21-13	3453-3460	WOT-100	_
21-14	3461-3467	system	_
21-15	3468-3469	;	_
21-16	3470-3477	Hitachi	_
21-17	3478-3495	High-Technologies	_
21-18	3496-3507	Corporation	_
21-19	3508-3509	,	_
21-20	3510-3515	Tokyo	_
21-21	3516-3517	,	_
21-22	3518-3523	Japan	_
21-23	3524-3525	)	_
21-24	3526-3527	,	_
21-25	3528-3530	as	_
21-26	3531-3541	previously	_
21-27	3542-3551	described	_
21-28	3552-3553	.	_

22-1	3554-3561	Briefly	_
22-2	3562-3563	,	_
22-3	3564-3567	the	_
22-4	3568-3574	device	_
22-5	3575-3583	measured	_
22-6	3584-3592	relative	_
22-7	3593-3600	changes	_
22-8	3601-3603	in	_
22-9	3604-3615	oxygenated-	_
22-10	3616-3617	(	_
22-11	3618-3622	oxy-	_
22-12	3623-3624	)	_
22-13	3625-3628	and	_
22-14	3629-3642	deoxygenated-	_
22-15	3643-3644	(	_
22-16	3645-3651	deoxy-	_
22-17	3652-3653	)	_
22-18	3654-3665	haemoglobin	_
22-19	3666-3667	(	_
22-20	3668-3670	Hb	_
22-21	3671-3672	)	_
22-22	3673-3687	concentrations	_
22-23	3688-3693	using	_
22-24	3694-3697	two	_
22-25	3698-3709	wavelengths	_
22-26	3710-3711	(	_
22-27	3712-3715	705	_
22-28	3716-3719	and	_
22-29	3720-3723	830	_
22-30	3724-3726	nm	_
22-31	3727-3728	)	_
22-32	3729-3733	with	_
22-33	3734-3735	a	_
22-34	3736-3744	sampling	_
22-35	3745-3749	rate	_
22-36	3750-3752	of	_
22-37	3753-3756	200	_
22-38	3757-3760	ms.	_
22-39	3761-3768	Optical	_
22-40	3769-3773	data	_
22-41	3774-3778	were	_
22-42	3779-3787	analysed	_
22-43	3788-3793	using	_
22-44	3794-3797	the	_
22-45	3798-3806	modified	_
22-46	3807-3819	Beer–Lambert	_
22-47	3820-3823	law	_
22-48	3824-3826	to	_
22-49	3827-3836	calculate	_
22-50	3837-3840	the	_
22-51	3841-3848	signals	_
22-52	3849-3859	reflecting	_
22-53	3860-3867	changes	_
22-54	3868-3870	in	_
22-55	3871-3873	Hb	_
22-56	3874-3880	levels	_
22-57	3881-3890	expressed	_
22-58	3891-3893	as	_
22-59	3894-3903	arbitrary	_
22-60	3904-3909	units	_
22-61	3910-3911	(	_
22-62	3912-3917	mM–mm	_
22-63	3918-3919	)	_
22-64	3920-3927	because	_
22-65	3928-3931	the	_
22-66	3932-3944	differential	_
22-67	3945-3949	path	_
22-68	3950-3957	lengths	_
22-69	3958-3960	of	_
22-70	3961-3964	the	_
22-71	3965-3976	wavelengths	_
22-72	3977-3980	are	_
22-73	3981-3991	indefinite	_
22-74	3992-3994	in	_
22-75	3995-3999	this	_
22-76	4000-4006	system	_
22-77	4007-4008	.	_

23-1	4009-4012	The	_
23-2	4013-4017	NIRS	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
23-3	4018-4023	probe	_
23-4	4024-4028	unit	_
23-5	4029-4032	has	_
23-6	4033-4034	a	_
23-7	4035-4036	2	_
23-8	4037-4038	×	_
23-9	4039-4040	4	_
23-10	4041-4052	alternating	_
23-11	4053-4064	arrangement	_
23-12	4065-4067	of	_
23-13	4068-4079	irradiation	_
23-14	4080-4083	and	_
23-15	4084-4093	detection	_
23-16	4094-4103	positions	_
23-17	4104-4105	.	_

24-1	4106-4109	The	_
24-2	4110-4116	lowest	_
24-3	4117-4123	probes	_
24-4	4124-4128	were	_
24-5	4129-4139	positioned	_
24-6	4140-4145	along	_
24-7	4146-4149	the	_
24-8	4150-4157	Fp1-Fp2	_
24-9	4158-4162	line	_
24-10	4163-4164	,	_
24-11	4165-4174	according	_
24-12	4175-4177	to	_
24-13	4178-4181	the	_
24-14	4182-4195	International	_
24-15	4196-4201	10–20	_
24-16	4202-4208	system	_
24-17	4209-4210	.	_

25-1	4211-4214	The	_
25-2	4215-4223	distance	_
25-3	4224-4231	between	_
25-4	4232-4237	pairs	_
25-5	4238-4240	of	_
25-6	4241-4249	emission	_
25-7	4250-4253	and	_
25-8	4254-4262	detector	_
25-9	4263-4269	probes	_
25-10	4270-4273	was	_
25-11	4274-4277	set	_
25-12	4278-4280	at	_
25-13	4281-4283	30	_
25-14	4284-4286	mm	_
25-15	4287-4288	,	_
25-16	4289-4292	and	_
25-17	4293-4296	the	_
25-18	4297-4308	measurement	_
25-19	4309-4313	area	_
25-20	4314-4321	between	_
25-21	4322-4325	the	_
25-22	4326-4332	probes	_
25-23	4333-4336	was	_
25-24	4337-4344	defined	_
25-25	4345-4347	as	_
25-26	4348-4349	a	_
25-27	4350-4357	channel	_
25-28	4358-4359	.	_

26-1	4360-4363	The	_
26-2	4364-4375	arrangement	_
26-3	4376-4378	of	_
26-4	4379-4387	channels	_
26-5	4388-4395	covered	_
26-6	4396-4399	the	_
26-7	4400-4406	entire	_
26-8	4407-4415	forehead	_
26-9	4416-4418	to	_
26-10	4419-4426	monitor	_
26-11	4427-4437	activation	_
26-12	4438-4440	in	_
26-13	4441-4451	prefrontal	_
26-14	4452-4459	regions	_
26-15	4460-4461	.	_

27-1	4462-4466	This	_
27-2	4467-4479	experimental	_
27-3	4480-4485	setup	_
27-4	4486-4489	was	_
27-5	4490-4502	corroborated	_
27-6	4503-4505	by	_
27-7	4506-4510	that	_
27-8	4511-4513	of	_
27-9	4514-4515	a	_
27-10	4516-4532	multi-individual	_
27-11	4533-4538	study	_
27-12	4539-4541	of	_
27-13	4542-4552	anatomical	_
27-14	4553-4567	craniocerebral	_
27-15	4568-4578	correction	_
27-16	4579-4584	using	_
27-17	4585-4588	the	_
27-18	4589-4602	International	_
27-19	4603-4608	10–20	_
27-20	4609-4615	system	_
27-21	4616-4617	.	_

28-1	4618-4635	Three-dimensional	_
28-2	4636-4647	coordinates	_
28-3	4648-4650	of	_
28-4	4651-4654	the	_
28-5	4655-4663	channels	_
28-6	4664-4668	were	_
28-7	4669-4677	obtained	_
28-8	4678-4682	from	_
28-9	4683-4686	six	_
28-10	4687-4694	healthy	_
28-11	4695-4703	subjects	_
28-12	4704-4709	using	_
28-13	4710-4711	a	_
28-14	4712-4729	three-dimensional	_
28-15	4730-4739	digitiser	_
28-16	4740-4741	(	_
28-17	4742-4749	Patriot	_
28-18	4750-4751	,	_
28-19	4752-4760	POLHEMUS	_
28-20	4761-4762	,	_
28-21	4763-4767	Inc.	_
28-22	4768-4769	,	_
28-23	4770-4780	Colchester	_
28-24	4781-4782	,	_
28-25	4783-4790	Vermont	_
28-26	4791-4792	,	_
28-27	4793-4796	USA	_
28-28	4797-4798	)	_
28-29	4799-4800	,	_
28-30	4801-4804	and	_
28-31	4805-4808	the	_
28-32	4809-4813	mean	_
28-33	4814-4822	estimate	_
28-34	4823-4826	for	_
28-35	4827-4830	the	_
28-36	4831-4838	spatial	_
28-37	4839-4851	registration	_
28-38	4852-4854	of	_
28-39	4855-4858	the	_
28-40	4859-4867	channels	_
28-41	4868-4873	using	_
28-42	4874-4877	the	_
28-43	4878-4905	probabilistic-determination	_
28-44	4906-4912	method	_
28-45	4913-4916	was	_
28-46	4917-4923	mapped	_
28-47	4924-4928	onto	_
28-48	4929-4932	the	_
28-49	4933-4941	Montreal	_
28-50	4942-4954	Neurological	_
28-51	4955-4964	Institute	_
28-52	4965-4970	space	_
28-53	4971-4976	based	_
28-54	4977-4979	on	_
28-55	4980-4988	NIRS-SPM	_
28-56	4989-4990	(	_
28-57	4991-4995	http	_
28-58	4996-4997	:	_
28-59	4998-5030	//bispl.weebly.com/nirs-spm.html	_
28-60	5031-5032	#	_
28-61	5033-5034	/	_
28-62	5035-5036	)	_
28-63	5037-5038	,	_
28-64	5039-5041	as	_
28-65	5042-5047	shown	_
28-66	5048-5050	in	_
28-67	5051-5054	Fig	_
28-68	5055-5056	.	_

29-1	5057-5059	3a	_
29-2	5060-5063	and	_
29-3	5064-5077	Supplementary	_
29-4	5078-5083	Table	_
29-5	5084-5086	S1	_
29-6	5087-5088	.	_

30-1	5089-5102	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
30-2	5103-5111	paradigm	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
30-3	5112-5115	For	_
30-4	5116-5119	the	_
30-5	5120-5133	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
30-6	5134-5145	acquisition	_
30-7	5146-5147	,	_
30-8	5148-5151	the	_
30-9	5152-5160	subjects	_
30-10	5161-5165	were	_
30-11	5166-5172	seated	_
30-12	5173-5175	in	_
30-13	5176-5177	a	_
30-14	5178-5189	comfortable	_
30-15	5190-5195	chair	_
30-16	5196-5198	in	_
30-17	5199-5200	a	_
30-18	5201-5207	silent	_
30-19	5208-5212	room	_
30-20	5213-5214	.	_

31-1	5215-5219	They	_
31-2	5220-5224	were	_
31-3	5225-5235	instructed	_
31-4	5236-5238	to	_
31-5	5239-5243	keep	_
31-6	5244-5249	their	_
31-7	5250-5254	eyes	_
31-8	5255-5259	open	_
31-9	5260-5263	and	_
31-10	5264-5270	remain	_
31-11	5271-5276	still	_
31-12	5277-5282	while	_
31-13	5283-5291	focusing	_
31-14	5292-5294	on	_
31-15	5295-5298	the	_
31-16	5299-5306	central	_
31-17	5307-5315	fixation	_
31-18	5316-5321	point	_
31-19	5322-5323	(	_
31-20	5324-5329	cross	_
31-21	5330-5334	hair	_
31-22	5335-5336	)	_
31-23	5337-5346	displayed	_
31-24	5347-5349	on	_
31-25	5350-5351	a	_
31-26	5352-5359	monitor	_
31-27	5360-5361	.	_

32-1	5362-5365	The	_
32-2	5366-5370	NIRS	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
32-3	5371-5382	measurement	_
32-4	5383-5392	commenced	_
32-5	5393-5397	when	_
32-6	5398-5401	the	_
32-7	5402-5407	cross	_
32-8	5408-5412	hair	_
32-9	5413-5421	appeared	_
32-10	5422-5424	on	_
32-11	5425-5428	the	_
32-12	5429-5436	monitor	_
32-13	5437-5440	and	_
32-14	5441-5450	continued	_
32-15	5451-5454	for	_
32-16	5455-5460	three	_
32-17	5461-5468	minutes	_
32-18	5469-5471	at	_
32-19	5472-5476	rest	_
32-20	5477-5478	.	_

33-1	5479-5483	Data	_
33-2	5484-5492	analysis	_
33-3	5493-5502	Magnitude	_
33-4	5503-5505	of	_
33-5	5506-5519	low-frequency	_
33-6	5520-5532	fluctuations	_
33-7	5533-5534	(	_
33-8	5535-5546	Δoxy-Hbpeak	_
33-9	5547-5548	)	_
33-10	5549-5557	Relative	_
33-11	5558-5565	changes	_
33-12	5566-5568	in	_
33-13	5569-5575	oxy-Hb	_
33-14	5576-5583	signals	_
33-15	5584-5588	were	_
33-16	5589-5597	analysed	_
33-17	5598-5607	according	_
33-18	5608-5610	to	_
33-19	5611-5612	a	_
33-20	5613-5621	previous	_
33-21	5622-5628	report	_
33-22	5629-5633	that	_
33-23	5634-5646	demonstrated	_
33-24	5647-5648	a	_
33-25	5649-5655	strong	_
33-26	5656-5667	correlation	_
33-27	5668-5675	between	_
33-28	5676-5682	oxy-Hb	_
33-29	5683-5687	NIRS	_
33-30	5688-5700	measurements	_
33-31	5701-5704	and	_
33-32	5705-5710	blood	_
33-33	5711-5722	oxygenation	_
33-34	5723-5738	level-dependent	_
33-35	5739-5746	signals	_
33-36	5747-5755	measured	_
33-37	5756-5761	using	_
33-38	5762-5766	fMRI	_
33-39	5767-5768	.	_

34-1	5769-5776	Further	_
34-2	5777-5778	,	_
34-3	5779-5787	relative	_
34-4	5788-5795	changes	_
34-5	5796-5798	in	_
34-6	5799-5807	deoxy-Hb	_
34-7	5808-5815	signals	_
34-8	5816-5820	were	_
34-9	5821-5829	analysed	_
34-10	5830-5845	supplementarily	_
34-11	5846-5847	.	_

35-1	5848-5851	The	_
35-2	5852-5856	time	_
35-3	5857-5864	courses	_
35-4	5865-5867	of	_
35-5	5868-5872	oxy-	_
35-6	5873-5876	and	_
35-7	5877-5885	deoxy-Hb	_
35-8	5886-5893	signals	_
35-9	5894-5898	were	_
35-10	5899-5909	diagrammed	_
35-11	5910-5915	using	_
35-12	5916-5919	the	_
35-13	5920-5939	BRainSuite_Analyzer	_
35-14	5940-5941	(	_
35-15	5942-5951	BRSystems	_
35-16	5952-5953	.	_

36-1	5954-5958	Inc.	_
36-2	5959-5960	,	_
36-3	5961-5969	Kanagawa	_
36-4	5970-5971	,	_
36-5	5972-5977	Japan	_
36-6	5978-5979	)	_
36-7	5980-5984	with	_
36-8	5985-5988	low	_
36-9	5989-5993	pass	_
36-10	5994-6000	filter	_
36-11	6001-6002	(	_
36-12	6003-6004	<	_
36-13	6005-6008	0.1	_
36-14	6009-6011	Hz	_
36-15	6012-6013	)	_
36-16	6014-6016	to	_
36-17	6017-6026	eliminate	_
36-18	6027-6040	physiological	_
36-19	6041-6047	noises	_
36-20	6048-6049	,	_
36-21	6050-6054	such	_
36-22	6055-6057	as	_
36-23	6058-6063	those	_
36-24	6064-6066	of	_
36-25	6067-6072	heart	_
36-26	6073-6077	beat	_
36-27	6078-6079	,	_
36-28	6080-6091	respiration	_
36-29	6092-6095	and	_
36-30	6096-6101	quick	_
36-31	6102-6106	body	_
36-32	6107-6116	movements	_
36-33	6117-6118	.	_

37-1	6119-6125	Figure	_
37-2	6126-6128	3b	_
37-3	6129-6137	presents	_
37-4	6138-6141	the	_
37-5	6142-6156	representative	_
37-6	6157-6161	time	_
37-7	6162-6168	course	_
37-8	6169-6171	of	_
37-9	6172-6176	oxy-	_
37-10	6177-6180	and	_
37-11	6181-6189	deoxy-Hb	_
37-12	6190-6197	signals	_
37-13	6198-6204	during	_
37-14	6205-6208	the	_
37-15	6209-6216	resting	_
37-16	6217-6222	state	_
37-17	6223-6224	.	_

38-1	6225-6227	To	_
38-2	6228-6237	represent	_
38-3	6238-6241	the	_
38-4	6242-6251	magnitude	_
38-5	6252-6254	of	_
38-6	6255-6268	low-frequency	_
38-7	6269-6281	fluctuations	_
38-8	6282-6288	during	_
38-9	6289-6292	the	_
38-10	6293-6300	resting	_
38-11	6301-6306	state	_
38-12	6307-6308	,	_
38-13	6309-6320	Δoxy-Hbpeak	_
38-14	6321-6324	was	_
38-15	6325-6332	indexed	_
38-16	6333-6335	as	_
38-17	6336-6339	the	_
38-18	6340-6344	peak	_
38-19	6345-6350	value	_
38-20	6351-6356	minus	_
38-21	6357-6360	the	_
38-22	6361-6367	lowest	_
38-23	6368-6373	value	_
38-24	6374-6377	for	_
38-25	6378-6384	oxy-Hb	_
38-26	6385-6392	signals	_
38-27	6393-6399	during	_
38-28	6400-6403	the	_
38-29	6404-6411	resting	_
38-30	6412-6417	state	_
38-31	6418-6419	(	_
38-32	6420-6423	Fig	_
38-33	6424-6425	.	_

39-1	6426-6428	3b	_
39-2	6429-6430	)	_
39-3	6431-6432	.	_

40-1	6433-6436	The	_
40-2	6437-6448	Δoxy-Hbpeak	_
40-3	6449-6452	was	_
40-4	6453-6463	calculated	_
40-5	6464-6467	for	_
40-6	6468-6471	the	_
40-7	6472-6474	10	_
40-8	6475-6485	individual	_
40-9	6486-6494	channels	_
40-10	6495-6497	of	_
40-11	6498-6502	NIRS	_
40-12	6503-6504	,	_
40-13	6505-6508	and	_
40-14	6509-6520	selectively	_
40-15	6521-6522	,	_
40-16	6523-6526	the	_
40-17	6527-6536	following	_
40-18	6537-6543	region	_
40-19	6544-6546	of	_
40-20	6547-6555	interest	_
40-21	6556-6557	(	_
40-22	6558-6561	ROI	_
40-23	6562-6563	)	_
40-24	6564-6567	was	_
40-25	6568-6574	chosen	_
40-26	6575-6577	to	_
40-27	6578-6585	examine	_
40-28	6586-6589	the	_
40-29	6590-6601	spontaneous	_
40-30	6602-6610	activity	_
40-31	6611-6612	.	_

41-1	6613-6616	The	_
41-2	6617-6620	ROI	_
41-3	6621-6624	was	_
41-4	6625-6628	set	_
41-5	6629-6631	as	_
41-6	6632-6640	channels	_
41-7	6641-6642	5	_
41-8	6643-6646	and	_
41-9	6647-6648	6	_
41-10	6649-6656	located	_
41-11	6657-6659	on	_
41-12	6660-6663	the	_
41-13	6664-6675	superficial	_
41-14	6676-6680	part	_
41-15	6681-6683	of	_
41-16	6684-6687	the	_
41-17	6688-6692	mPFC	_
41-18	6693-6694	,	_
41-19	6695-6698	and	_
41-20	6699-6703	then	_
41-21	6704-6705	,	_
41-22	6706-6709	the	_
41-23	6710-6721	Δoxy-Hbpeak	_
41-24	6722-6724	of	_
41-25	6725-6733	channels	_
41-26	6734-6735	5	_
41-27	6736-6739	and	_
41-28	6740-6741	6	_
41-29	6742-6746	were	_
41-30	6747-6755	averaged	_
41-31	6756-6759	for	_
41-32	6760-6763	the	_
41-33	6764-6767	ROI	_
41-34	6768-6774	signal	_
41-35	6775-6776	.	_

42-1	6777-6787	Fractional	_
42-2	6788-6797	Amplitude	_
42-3	6798-6800	of	_
42-4	6801-6804	the	_
42-5	6805-6808	low	_
42-6	6809-6818	frequency	_
42-7	6819-6831	fluctuations	_
42-8	6832-6833	(	_
42-9	6834-6839	fALFF	_
42-10	6840-6841	)	_
42-11	6842-6847	fALFF	_
42-12	6848-6851	was	_
42-13	6852-6862	calculated	_
42-14	6863-6868	using	_
42-15	6869-6872	the	_
42-16	6873-6883	ALFF/fALFF	_
42-17	6884-6892	software	_
42-18	6893-6894	(	_
42-19	6895-6904	BRSystems	_
42-20	6905-6909	Inc.	_
42-21	6910-6911	;	_
42-22	6912-6921	Brainsuit	_
42-23	6922-6926	ALFF	_
42-24	6927-6928	;	_
42-25	6929-6937	Kanagawa	_
42-26	6938-6939	,	_
42-27	6940-6945	Japan	_
42-28	6946-6947	)	_
42-29	6948-6957	according	_
42-30	6958-6960	to	_
42-31	6961-6969	previous	_
42-32	6970-6977	reports	_
42-33	6978-6979	.	_

43-1	6980-6982	In	_
43-2	6983-6987	this	_
43-3	6988-6996	software	_
43-4	6997-6998	,	_
43-5	6999-7004	first	_
43-6	7005-7006	,	_
43-7	7007-7010	the	_
43-8	7011-7015	time	_
43-9	7016-7022	series	_
43-10	7023-7026	for	_
43-11	7027-7031	each	_
43-12	7032-7039	channel	_
43-13	7040-7043	was	_
43-14	7044-7055	transformed	_
43-15	7056-7058	to	_
43-16	7059-7060	a	_
43-17	7061-7070	frequency	_
43-18	7071-7077	domain	_
43-19	7078-7083	using	_
43-20	7084-7087	the	_
43-21	7088-7092	fast	_
43-22	7093-7100	Fourier	_
43-23	7101-7110	transform	_
43-24	7111-7112	,	_
43-25	7113-7116	and	_
43-26	7117-7120	the	_
43-27	7121-7126	power	_
43-28	7127-7135	spectrum	_
43-29	7136-7139	was	_
43-30	7140-7148	obtained	_
43-31	7149-7150	.	_

44-1	7151-7155	Then	_
44-2	7156-7157	,	_
44-3	7158-7161	the	_
44-4	7162-7168	square	_
44-5	7169-7173	root	_
44-6	7174-7177	was	_
44-7	7178-7188	calculated	_
44-8	7189-7191	at	_
44-9	7192-7196	each	_
44-10	7197-7206	frequency	_
44-11	7207-7209	of	_
44-12	7210-7213	the	_
44-13	7214-7219	power	_
44-14	7220-7228	spectrum	_
44-15	7229-7230	.	_

45-1	7231-7234	The	_
45-2	7235-7238	sum	_
45-3	7239-7241	of	_
45-4	7242-7245	the	_
45-5	7246-7252	square	_
45-6	7253-7257	root	_
45-7	7258-7264	across	_
45-8	7265-7268	the	_
45-9	7269-7282	low-frequency	_
45-10	7283-7288	range	_
45-11	7289-7290	(	_
45-12	7291-7300	0.01–0.08	_
45-13	7301-7303	Hz	_
45-14	7304-7305	)	_
45-15	7306-7309	was	_
45-16	7310-7317	divided	_
45-17	7318-7320	by	_
45-18	7321-7325	that	_
45-19	7326-7332	across	_
45-20	7333-7336	the	_
45-21	7337-7343	entire	_
45-22	7344-7353	frequency	_
45-23	7354-7359	range	_
45-24	7360-7361	(	_
45-25	7362-7368	0–0.25	_
45-26	7369-7371	Hz	_
45-27	7372-7373	)	_
45-28	7374-7376	to	_
45-29	7377-7386	calculate	_
45-30	7387-7392	fALFF	_
45-31	7393-7394	.	_

46-1	7395-7398	The	_
46-2	7399-7404	fALFF	_
46-3	7405-7408	was	_
46-4	7409-7417	analysed	_
46-5	7418-7421	for	_
46-6	7422-7425	ROI	_
46-7	7426-7428	as	_
46-8	7429-7437	selected	_
46-9	7438-7440	in	_
46-10	7441-7444	the	_
46-11	7445-7453	previous	_
46-12	7454-7461	section	_
46-13	7462-7463	.	_

47-1	7464-7475	Statistical	_
47-2	7476-7484	analysis	_
47-3	7485-7498	Between-group	_
47-4	7499-7509	difference	_
47-5	7510-7512	of	_
47-6	7513-7516	the	_
47-7	7517-7522	NIIRS	_
47-8	7523-7527	data	_
47-9	7528-7535	between	_
47-10	7536-7539	the	_
47-11	7540-7548	patients	_
47-12	7549-7553	with	_
47-13	7554-7567	schizophrenia	_
47-14	7568-7571	and	_
47-15	7572-7579	healthy	_
47-16	7580-7588	subjects	_
47-17	7589-7592	was	_
47-18	7593-7601	examined	_
47-19	7602-7607	using	_
47-20	7608-7609	a	_
47-21	7610-7617	general	_
47-22	7618-7624	linear	_
47-23	7625-7630	model	_
47-24	7631-7635	with	_
47-25	7636-7639	the	_
47-26	7640-7658	Δoxy−/deoxy-Hbpeak	_
47-27	7659-7661	or	_
47-28	7662-7667	fALFF	_
47-29	7668-7670	as	_
47-30	7671-7680	dependent	_
47-31	7681-7690	variables	_
47-32	7691-7692	,	_
47-33	7693-7698	group	_
47-34	7699-7700	(	_
47-35	7701-7709	patients	_
47-36	7710-7714	with	_
47-37	7715-7736	schizophrenia/healthy	_
47-38	7737-7745	subjects	_
47-39	7746-7747	)	_
47-40	7748-7750	as	_
47-41	7751-7752	a	_
47-42	7753-7768	between-subject	_
47-43	7769-7775	factor	_
47-44	7776-7779	and	_
47-45	7780-7783	age	_
47-46	7784-7786	as	_
47-47	7787-7788	a	_
47-48	7789-7798	covariate	_
47-49	7799-7800	.	_

48-1	7801-7803	To	_
48-2	7804-7811	examine	_
48-3	7812-7815	the	_
48-4	7816-7829	relationships	_
48-5	7830-7837	between	_
48-6	7838-7841	the	_
48-7	7842-7860	Δoxy−/deoxy-Hbpeak	_
48-8	7861-7863	or	_
48-9	7864-7869	fALFF	_
48-10	7870-7873	and	_
48-11	7874-7882	clinical	_
48-12	7883-7892	variables	_
48-13	7893-7895	in	_
48-14	7896-7904	patients	_
48-15	7905-7909	with	_
48-16	7910-7923	schizophrenia	_
48-17	7924-7925	,	_
48-18	7926-7934	Spearman	_
48-19	7935-7936	’	_
48-20	7937-7938	s	_
48-21	7939-7950	correlation	_
48-22	7951-7962	coefficient	_
48-23	7963-7964	(	_
48-24	7965-7967	rs	_
48-25	7968-7969	)	_
48-26	7970-7973	was	_
48-27	7974-7983	initially	_
48-28	7984-7992	analysed	_
48-29	7993-7994	.	_

49-1	7995-7997	If	_
49-2	7998-8001	any	_
49-3	8002-8014	significance	_
49-4	8015-8018	was	_
49-5	8019-8024	found	_
49-6	8025-8026	,	_
49-7	8027-8035	multiple	_
49-8	8036-8046	regression	_
49-9	8047-8055	analysis	_
49-10	8056-8059	was	_
49-11	8060-8069	conducted	_
49-12	8070-8074	with	_
49-13	8075-8078	the	_
49-14	8079-8083	NIRS	_
49-15	8084-8096	measurements	_
49-16	8097-8099	as	_
49-17	8100-8109	dependent	_
49-18	8110-8119	variables	_
49-19	8120-8121	,	_
49-20	8122-8129	thereby	_
49-21	8130-8141	controlling	_
49-22	8142-8145	for	_
49-23	8146-8151	other	_
49-24	8152-8161	potential	_
49-25	8162-8173	confounding	_
49-26	8174-8183	variables	_
49-27	8184-8185	(	_
49-28	8186-8189	age	_
49-29	8190-8193	and	_
49-30	8194-8207	antipsychotic	_
49-31	8208-8212	dose	_
49-32	8213-8214	)	_
49-33	8215-8216	,	_
49-34	8217-8220	and	_
49-35	8221-8226	added	_
49-36	8227-8234	factors	_
49-37	8235-8239	such	_
49-38	8240-8242	as	_
49-39	8243-8246	GAF	_
49-40	8247-8250	and	_
49-41	8251-8257	CRDPSS	_
49-42	8258-8264	scores	_
49-43	8265-8266	.	_

50-1	8267-8270	The	_
50-2	8271-8280	threshold	_
50-3	8281-8284	for	_
50-4	8285-8288	the	_
50-5	8289-8301	significance	_
50-6	8302-8304	of	_
50-7	8305-8313	p-values	_
50-8	8314-8317	was	_
50-9	8318-8321	set	_
50-10	8322-8324	at	_
50-11	8325-8329	0.05	_
50-12	8330-8331	.	_

51-1	8332-8335	All	_
51-2	8336-8347	statistical	_
51-3	8348-8353	tests	_
51-4	8354-8358	were	_
51-5	8359-8369	two-tailed	_
51-6	8370-8373	and	_
51-7	8374-8378	were	_
51-8	8379-8388	performed	_
51-9	8389-8394	using	_
51-10	8395-8403	GraphPad	_
51-11	8404-8409	Prism	_
51-12	8410-8413	6.0	_
51-13	8414-8417	for	_
51-14	8418-8425	Windows	_
51-15	8426-8433	version	_
51-16	8434-8438	6.07	_
51-17	8439-8440	(	_
51-18	8441-8449	GraphPad	_
51-19	8450-8458	Software	_
51-20	8459-8460	,	_
51-21	8461-8465	Inc.	_
51-22	8466-8467	,	_
51-23	8468-8470	La	_
51-24	8471-8476	Jolla	_
51-25	8477-8478	,	_
51-26	8479-8481	CA	_
51-27	8482-8483	,	_
51-28	8484-8487	USA	_
51-29	8488-8489	)	_
51-30	8490-8492	or	_
51-31	8493-8497	SPSS	_
51-32	8498-8505	version	_
51-33	8506-8510	25.0	_
51-34	8511-8512	(	_
51-35	8513-8516	IBM	_
51-36	8517-8521	Inc.	_
51-37	8522-8523	,	_
51-38	8524-8527	New	_
51-39	8528-8532	York	_
51-40	8533-8534	,	_
51-41	8535-8538	USA	_
51-42	8539-8540	)	_
51-43	8541-8542	.	_

52-1	8543-8552	Exclusion	_
52-2	8553-8555	of	_
52-3	8556-8561	probe	_
52-4	8562-8567	error	_
52-5	8568-8576	channels	_
52-6	8577-8583	Within	_
52-7	8584-8587	the	_
52-8	8588-8590	10	_
52-9	8591-8599	channels	_
52-10	8600-8608	measured	_
52-11	8609-8614	using	_
52-12	8615-8619	NIRS	_
52-13	8620-8621	,	_
52-14	8622-8627	those	_
52-15	8628-8634	judged	_
52-16	8635-8637	to	_
52-17	8638-8640	be	_
52-18	8641-8646	probe	_
52-19	8647-8653	errors	_
52-20	8654-8657	for	_
52-21	8658-8662	each	_
52-22	8663-8670	subject	_
52-23	8671-8673	by	_
52-24	8674-8677	the	_
52-25	8678-8685	WOT-100	_
52-26	8686-8694	software	_
52-27	8695-8699	were	_
52-28	8700-8708	excluded	_
52-29	8709-8713	from	_
52-30	8714-8717	the	_
52-31	8718-8726	analysis	_
52-32	8727-8728	.	_

53-1	8729-8738	According	_
53-2	8739-8741	to	_
53-3	8742-8746	this	_
53-4	8747-8756	criterion	_
53-5	8757-8758	,	_
53-6	8759-8761	ch	_
53-7	8762-8763	.	_

54-1	8764-8765	1	_
54-2	8766-8769	and	_
54-3	8770-8772	ch	_
54-4	8773-8774	.	_

55-1	8775-8776	9	_
55-2	8777-8781	were	_
55-3	8782-8790	excluded	_
55-4	8791-8794	for	_
55-5	8795-8798	one	_
55-6	8799-8806	healthy	_
55-7	8807-8814	subject	_
55-8	8815-8818	and	_
55-9	8819-8821	ch	_
55-10	8822-8823	.	_

56-1	8824-8826	10	_
56-2	8827-8830	was	_
56-3	8831-8839	excluded	_
56-4	8840-8843	for	_
56-5	8844-8847	two	_
56-6	8848-8849	.	_

57-1	8850-8852	In	_
57-2	8853-8866	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
57-3	8867-8868	,	_
57-4	8869-8871	ch	_
57-5	8872-8873	.	_

58-1	8874-8875	2	_
58-2	8876-8879	and	_
58-3	8880-8882	ch	_
58-4	8883-8884	.	_

59-1	8885-8886	3	_
59-2	8887-8891	were	_
59-3	8892-8900	excluded	_
59-4	8901-8904	for	_
59-5	8905-8908	two	_
59-6	8909-8917	patients	_
59-7	8918-8919	,	_
59-8	8920-8922	ch	_
59-9	8923-8924	.	_

60-1	8925-8926	7	_
60-2	8927-8930	and	_
60-3	8931-8933	ch	_
60-4	8934-8935	.	_

61-1	8936-8937	9	_
61-2	8938-8942	were	_
61-3	8943-8951	excluded	_
61-4	8952-8955	for	_
61-5	8956-8959	one	_
61-6	8960-8961	,	_
61-7	8962-8964	ch	_
61-8	8965-8966	.	_

62-1	8967-8968	8	_
62-2	8969-8972	was	_
62-3	8973-8981	excluded	_
62-4	8982-8985	for	_
62-5	8986-8991	three	_
62-6	8992-8993	,	_
62-7	8994-8997	and	_
62-8	8998-9000	ch	_
62-9	9001-9002	.	_

63-1	9003-9005	10	_
63-2	9006-9009	was	_
63-3	9010-9018	excluded	_
63-4	9019-9022	for	_
63-5	9023-9028	seven	_
63-6	9029-9030	.	_

64-1	9031-9038	Notably	_
64-2	9039-9040	,	_
64-3	9041-9043	ch	_
64-4	9044-9045	.	_

65-1	9046-9047	4	_
65-2	9048-9049	,	_
65-3	9050-9052	ch	_
65-4	9053-9054	.	_

66-1	9055-9056	5	_
66-2	9057-9060	and	_
66-3	9061-9063	ch	_
66-4	9064-9065	.	_

67-1	9066-9067	6	_
67-2	9068-9072	were	_
67-3	9073-9079	intact	_
67-4	9080-9083	for	_
67-5	9084-9087	all	_
67-6	9088-9095	healthy	_
67-7	9096-9104	subjects	_
67-8	9105-9108	and	_
67-9	9109-9117	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
67-10	9118-9122	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
67-11	9123-9136	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
67-12	9137-9138	.	_

